INSPECS Group plc (LON:SPEC – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as GBX 87 and last traded at GBX 84.50, with a volume of 566 shares changing hands. The stock had previously closed at GBX 84.50.
INSPECS Group Price Performance
The firm has a market capitalization of £85.91 million, a P/E ratio of -8.99 and a beta of 1.67. The company has a debt-to-equity ratio of 74.99, a current ratio of 1.32 and a quick ratio of 0.89. The stock’s fifty day simple moving average is GBX 83.08 and its 200 day simple moving average is GBX 77.67.
INSPECS Group (LON:SPEC – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported GBX 7.28 EPS for the quarter. The firm had revenue of £191.70 million during the quarter. INSPECS Group had a negative net margin of 2.67% and a negative return on equity of 6.07%. On average, equities research analysts predict that INSPECS Group plc will post 5.5500982 EPS for the current year.
INSPECS Group Company Profile
Inspecs is a designer, manufacturer and distributor of eyewear frames. The Group produces a broad range of frames, covering optical, sunglasses and safety, which are either “Branded” (either under licence or under the Group’s own proprietary brands), or “OEM” (including private label on behalf of retail customers and un-branded). As one of only a few companies that can offer this one-stop-shop solution to global retail chains, Inspecs is well positioned to continue to take market share in the globally expanding eyewear market.
Inspecs customers include global optical and non-optical retailers, global distributors and independent opticians, with its distribution network covering over 80 countries and reaching approximately 30,000 points of sale.
Read More
- Five stocks we like better than INSPECS Group
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for INSPECS Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INSPECS Group and related companies with MarketBeat.com's FREE daily email newsletter.
